Parma, January 29th, 2025 – Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and Daphne Quimi. Following a global search, the new Board members have joined the current five at Chiesi, effective January 28th, 2025.
The addition of three new NEDs is a significant part of Chiesi's broader strategy to enhance the Board’s capabilities, focusing on both upskilling and further internationalizing its leadership.
Driven by the continued foresight of the Chiesi family, this step represents a clear advancement in the company's efforts to enrich corporate governance as part of its ongoing international and patient impact growth. The new NEDs bring valuable expertise that will guide the company towards industry best practices.
By fostering diversity and introducing new competencies, they will support Chiesi’s commitment to sustainable growth, organizational transition, and international expansion, including into the important US market.
Furthermore, with the inclusion of these new members, Chiesi has also improved its Board functionality, particularly through the establishment of internal committees designed to enhance decision-making processes. The new committees are set up as follows:
Each of the new Board members brings extensive experience to support Chiesi adapt to the rapidly evolving marketplace and continue its evolution:
Roch Doliveux has extensive leadership experience in Biopharmaceuticals and was CEO of UCB for ten years. He chairs the Boards of Pierre Fabre SA and Oxford Biomedica.
Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ArQule, leading it until its acquisition by Merck & Co. in 2020, and he held senior roles at Bayer Schering Pharma. He serves on the Boards of Replimune Group, Merus and West Pharmaceutical Services.
Daphne Quimi has made significant contributions to the pharmaceutical industry. As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. She also held senior roles at Johnson & Johnson, Bristol-Myers Squibb and Avon. She serves on the Boards of Amylyx Pharmaceuticals and Century Therapeutics.
“We are thrilled to welcome Roch Doliveux, Paolo Pucci, and Daphne Quimi to our Board”, says Alessandro Chiesi, Chair. “Their experiences will enhance Chiesi’s governance and support our global ambitions. In line with our family’s vision, this move further reflects our commitment to constant improvement, and will allow us to even better focus on the strategic drivers of our company. It will benefit the Group as we continue to grow and internationalize, and we look forward to the positive impact they will bring.”
“I am confident Roch, Paolo, and Daphne will be excellent additions to the Chiesi Board,” says Giuseppe Accogli, CEO. “They all bring extensive international experience and diverse expertise, which will enhance our competitiveness. Their fresh perspectives and valuable skills will enrich our Board discussions, and strengthen our governance framework, which will help to unlock our potential to improve and develop as a company.”
About Chiesi Group
Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com
About the new Non-Executive Directors:
Roch Doliveux has driven innovation and growth in healthcare through various leadership roles. He facilitated collaboration in medical research as Chairman of the Innovative Medicines Initiative and GLG Institute Healthcare. His previous NED roles included UCB and Stryker (USA). Currently, he chairs the Boards of Pierre Fabre Group and Oxford Biomedica, where he continues to contribute to advancing healthcare and mental health initiatives. Doliveux is a Swiss national.
Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ARQULE, leading it until its acquisition by Merck & Co. in 2020. At Bayer Schering Pharma, he held senior roles, including President of Global Oncology. His tenure at Eli Lilly included leadership positions in Sweden and Italy. Pucci also has extensive NED experience, serving on the Boards of companies like Merus NV, Tarus Therapeutics, and Replimune Group. Pucci is a dual US-Italian national.
Daphne Quimi has made significant contributions to the pharmaceutical industry. As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. With 13 years at Johnson & Johnson, she gained extensive experience in audit, FP&A, and reporting. She serves on the boards of Amylyx Pharmaceuticals and Century Therapeutics, playing key roles in IPOs, acquisitions and CEO transitions. Quimi is a US national.